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A new blaOXA-258 gene is described as a species-specific taxonomic marker for Achromobacter ruhlandii isolates (all recovered
from cystic fibrosis patients). Even though OXA-258 differs from OXA-114 variants, isolates could be misidentified as A. xiloxo-
sidans by the amplification of an inner fragment from the OXA-coding gene. A robust identification of A. ruhlandii can be
achieved by sequencing this single OXA gene, as well as by a more laborious recently proposed multilocus sequence-typing
(MLST) scheme.
Although Achromobacter xylosoxidans was the only specieswhen the genus Achromobacter was proposed (1), the genus
currently comprises several species: A. xylosoxidans (the type spe-
cies of the genus), A. denitrificans, A. insolitus, A. marplatensis, A.
piechaudii, A. ruhlandii, and A. spanius (2). A. ruhlandii and
A. piechaudii were reassigned from the genus Alcaligenes, while A.
xylosoxidans subsp. denitrificans was reclassified as A. denitrificans
(3). A. spanius, A. insolitus, and A. marplatensis were described
later (4, 5). Moreover, the existence of several additional species,
such as A. animicus, A. mucicolens, A. pulmonis, and A. spiritinus,
has been recently reported (6, 7), so the taxonomic complexity of
the genus is expected to increase.
A. xylosoxidans is recognized as being capable of causing per-
sistent respiratory tract infections in cystic fibrosis (CF) patients,
although its pathogenic role in disease progression remains to be
elucidated (8). Prevalence rates of Achromobacter spp. recovered
from respiratory secretions have increased in recent years, proba-
bly due to the extended life span of CF patients and the selective
pressure imposed by multiple-antimicrobial therapy, but also to
improved microbiological and molecular techniques (9).
Accurate species identification of Achromobacter isolates is dif-
ficult, and clinical isolates of Achromobacter are mostly referred as
A. xylosoxidans. Also, Achromobacter species other than A. xy-
losoxidans have been considered environmental inhabitants and
only recently associated with human infections (6, 9, 10). How-
ever, a clone of A. ruhlandii, designated the Danish epidemic
strain (DES), spread among CF patients in Denmark in 2006, and
its dissemination could not be stopped despite the control mea-
sures applied (10, 11).
In this study, different phenotype-based techniques and mo-
lecular tools were used to characterize Achromobacter isolates re-
covered from CF patients.
Twenty-eight clinical isolates of Achromobacter recovered from
CF patients were included. Isolates were derived from respiratory
secretions (19 isolates), blood (5 isolates), urine (2 isolates), skin
and soft tissues (1 isolate), and bone (1 isolate). Phenotypic iden-
tification was performed by conventional biochemical tests and
API 20 NE (bioMérieux) (3, 7). Twenty-three isolates could be
identified as A. xylosoxidans. However, the results obtained for five
isolates (namely, 38, 39, 67, 80, and 319) were not conclusive to
identify them at the species level (Table 1). According to Van-
damme et al. (7), these five isolates could correspond to A. ruh-
landii, as galactose oxidation and nitrite reduction were negative;
these reactions have been proposed as differentiating tests for the
identification of Achromobacter species. Growth on acetamide has
also been mentioned as a differential reaction, rendering positive
results for A. xylosoxidans and negative results for A. ruhlandii;
however, all the isolates included in this study except one (isolate
67) rendered a positive result. Bio codes and identification results
obtained using the API 20 NE System (bioMérieux) are shown in
Table 2.
Total protein extracts for these five isolates and a previously
characterized A. xylosoxidans strain were obtained as previously
described (12). Electrophoretical total protein profiles in 12%
SDS-PAGE were identical among isolates 38, 39, 67, 80, and 319
but different from those of A. xylosoxidans.
The 16S rRNA gene was amplified by PCR (13). Purified am-
plicons were sequenced in both strands using an ABI Prism DNA
3700 sequencer and compared with databases using NCBI’s
BLAST. They displayed about 99% identity to the sequences of
different species of Achromobacter and were unable to discrimi-
nate among them.
A multilocus sequence-typing (MLST) scheme was conducted
to identify species of Achromobacter in those isolates that could
not be unambiguously identified by biochemical reactions. For
this, fragments of seven conserved housekeeping genes were am-
plified and sequenced, as recently described (6). Allele profiles and
sequence types (ST) were assigned according to the Achromobacter
MLST website (http://pubmlst.org/achromobacter/). Isolate 319
displayed the following alleles: nusA, 19; rpoB, 33; eno, 5; gtlB, 15;
lepA, 47; nuoL, 19; and nrdA, 12, corresponding to A. ruhlandii ST
43. The other four isolates (38, 39, 67, and 80) displayed new
alleles for three of these seven genes, showing the following allelic
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profile: nusA, 17; rpoB, 32; eno, 74; gtlB, 7; lepA, 80; nuoL, 19; and
nrdA, 73, belonging to a new ST assigned as ST 148. An alignment
of the concatenated sequences (2,254 nucleotides) of these seven
fragments with those corresponding to 142 Achromobacter spp.
available in the database was conducted using the Clustal X 2.1
program. The statistical selection of the best-fit model of nucleo-
tide substitution was assayed by JModelTest. Maximum-likeli-
hood estimation was conducted using PhyML 3.0, while the dis-
tances method was performed using the MEGA5 program. A
bootstrap with 1,000 resample matrices for both methods was
executed to assess the statistical support for the identified groups
(14). The dendrogram obtained with maximun likelihood is de-
picted in Fig. 1, showing that these five isolates grouped with A.
ruhlandii strains. A similar tree was achieved when applying the
distance method (data not shown).
The presence of the A. xylosoxidans species-specific marker
blaOXA-114 was investigated by PCR amplification as described by
Turton et al. (15) with positive amplification in all isolates. Puri-
fied amplicons were sequenced in both strands as described above,
and the nucleotide sequences were compared with those of all the
different blaOXA-114 allelic variants deposited in GenBank. Ampli-
cons obtained from the isolates identified as A. xylosoxidans dis-
played 99 to 100% identity to the blaOXA-114 variants. However,
the nucleotide sequences of the amplicons corresponding to the
five A. ruhlandii isolates differed significantly from those of all the
blaOXA-114 alleles. The complete sequence for the new blaOXA gene
was obtained using a thermal asymmetric interlaced (TAIL)-PCR
approach (16). The enzyme was assigned the number OXA-258.
This new class D -lactamase differed from OXA-114a by 40
amino acids, displaying 85% identity (Fig. 2). Also, a variant of the
enzyme, referred to here as OXA-258a, that differed in 1 amino
acid was found in A. ruhlandii 319, corresponding to OXA-258b
(Fig. 2).
Restriction sites of different endonucleases were inferred in
silico for all blaOXA-114 allelic variants deposited in GenBank in
order to design an accurate restriction fragment length polymor-
phism (RFLP) PCR assay able to differentiate the blaOXA-258 gene
from all blaOXA-114 variants. ApaI (Amersham Phamacia Biotech)
was used to digest the amplicons obtained by the PCR proposed by
Turton et al. (15). For this, amplicons were incubated with 15 U of
this restriction enzyme for 2 h at 37°C. As expected, ApaI was able
TABLE 1 Biochemical identification of Achromobacter sp. isolates
Biochemical test
Resultsa for:
Clinical isolates Control strainsb
Ax










Glucose         () 
Lactose          
Galactose          
Maltose          
Sucrose          
Fructose          
Manitol          
Xilose         () 
Glycerol ()    ()  () ()  
L-Arabinose         () 
D-Arabinose ()      ()   
Growth on acetamide       NEd NE NE NE
Urea-Christensen          
Hydrolysis of esculin          
Nitrate reduction          
Nitrite reduction          
Arginine dehydrolase          
Pyre hydrolysis       NE NE NE NE
a , positive; (), delayed reaction; , negative.
b Data from reference 3.
c Clinical isolates identified as A. Xylosoxidans (n  23).
d NE, not evaluated in reference 3.
e Pyr, p-naphthylamide pyrrolidonyl.
TABLE 2 Biochemical identification performed with the API 20 NE
system
Clinical isolate Bio code Identification (%)
Ax isolatesa (n  23)
n  12 1042477 A. xylosoxidans (99.9)
n  8 1042467 A. xylosoxidans (99.9)
n  3 1040477 A. xylosoxidans (94.5)
38 1042465 A. xylosoxidans (92.2)
39 1042465 A. xylosoxidans (92.2)
67 1040467 A. xylosoxidans (89.4)
80 1000465 A. denitrificans (46.7)
319 1042467 A. xylosoxidans (99.9)
a Clinical isolates identified as A. xylosoxidans.
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to digest blaOXA-258 amplicons obtained from A. ruhlandii isolates
but none of those for blaOXA-114 variants obtained from A. xy-
losoxidans isolates.
Although at present Achromobacter is considered an emerging
pathogen in CF patients, species of the genus are frequently mis-
identified (10, 11). Identification based on biochemical reactions
was awkward and sometimes subjective and was conclusive only
for true A. xylosoxidans isolates. In agreement with recent reports
(6, 15), ARNr 16S gene sequencing was not able to discriminate
among different species of Achromobacter. CLSI recommenda-
tions proposing this tool, when the phenotypic approach was not
enough for species level identification (17), were made before the
publication of the majority of today’s species within the genus.
In 2008, the A. xylosoxidans species-specific class D -lacta-
mase OXA-114 was described (18), and later, in 2011, Turton et al.
proposed the identification of the species based on the PCR am-
plification of an inner fragment of the coding gene (15). In our
hands, not only A. xylosoxidans isolates, but also A. ruhlandii ren-
dered positive amplifications, leading to the description of a new
OXA-coding gene when A. ruhlandii amplicons were sequenced.
This highlights the fact that amplification of the inner fragment
without further sequencing, as initially described, may be mislead-
ing, resulting in the misidentification of some species of Achromo-
bacter. A robust identification may be achieved by sequencing only
this blaOXA gene, as well as with the MLST scheme recently pro-
posed (6), based on a comparison of either the allelic profiles or
the concatenated sequences. Both display remarkable discrimina-
tory power among Achromobacter species, allowing the identifica-
tion of A. ruhlandii isolates. However, ApaI-based fragment re-
striction may constitute a convenient alternative to discriminate
between blaOXA-258, described in the present study and ubiquitous
in A. ruhlandii, and the blaOXA-114 variants present in A. xylosoxi-
dans, leading to accurate, easy, and fast identification in laborato-
ries that may not be able to achieve sequencing.
It is clear that not only A. xylosoxidans represents the genus in
these patient secretions, suggesting that the roles of the other spe-
cies need to be reevaluated and that proper identification is abso-
lutely necessary to understand the epidemiology and clinical im-
pact of the different Achromobacter species in this pathology and
to guide proper antimicrobial therapy.
FIG 1 Dendrogram based on maximum-likelihood estimation conducted using PhyML 3.0 for 147 Achromobacter sp. concatenated housekeeping genes.
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Nucleotide sequence accession numbers. The sequences for
the enzymes OXA-258 and OXA-258a were assigned GenBank
accession numbers EMBL HE614014.1 and EMBL HF562855, re-
spectively.
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